keyword
MENU ▼
Read by QxMD icon Read
search

B-cell lymphoma

keyword
https://www.readbyqxmd.com/read/29909154/outcomes-of-relapsed-and-refractory-primary-mediastinal-thymic-large-b-cell-lymphoma-treated-with-second-line-therapy-and-intent-to-transplant
#1
Santosha Vardhana, Paul A Hamlin, Joanna Yang, Andrew Zelenetz, Craig S Sauter, Matthew J Matasar, Andy Ni, Joachim Yahalom, Craig H Moskowitz
Primary mediastinal (thymic) large B-cell lymphoma is a subtype of diffuse large B-cell lymphoma with distinct clinical, molecular and genetic features, many of which overlap with Hodgkin's lymphoma. Increasingly, initial therapy for these patients has employed dose-dense chemotherapy with or without radiation with excellent results. In patients with relapsed and primary refractory disease, outcomes of second-line therapy followed by consolidation with high-dose therapy and autologous stem cell transplantation remains largely undefined...
June 14, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29909151/hematogones-predict-better-outcome-in-allogeneic-hematopoietic-stem-cell-transplantation-irrespective-of-graft-sources
#2
Takashi Ishio, Junichi Sugita, Takahiro Tateno, Daisuke Hidaka, Eiko Hayase, Souichi Shiratori, Kohei Okada, Hideki Goto, Masahiro Onozawa, Masao Nakagawa, Daigo Hashimoto, Kaoru Kahata, Katsuya Fujimoto, Tomoyuki Endo, Takeshi Kondo, Takanori Teshima
Benign precursors of B lymphocytes, termed hematogones, are observed in the regenerative state of hematopoiesis following chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT). Previous studies have demonstrated that expansion of hematogones correlates with better clinical outcomes after allo-HSCT. We retrospectively analyzed the association between hematogones and clinical outcomes in 309 consecutive patients undergone allo-HSCT, which was the largest population-based cohort reported so far...
June 14, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29908894/microrna-499a-decelerates-glioma-cell-proliferation-while-accelerating-apoptosis-through-the-suppression-of-notch1-and-the-mapk-signaling-pathway
#3
Bang-Qing Wang, Bin Yang, Hua-Chao Yang, Jun-Yi Wang, Sen Hu, Yu-Shuai Gao, Xing-Yao Bu
As the most common and lethal of intracranial tumors, glioma accounts for 81% of all malignant brain tumors. Research data has identified the role of microRNAs (miRs) as functional suppressers in the progression of Glioma. The present study aimed to, ascertain as to whether microRNA-499a (miR-499a) influences cell proliferation and apoptosis through the MAPK signaling pathway by targeting Notch1 in glioma. Both glioma and adjacent tissues between 2012~2016, were obtained from People's Hospital of Zhengzhou University (Henan Provincial People's Hospital)...
June 14, 2018: Brain Research Bulletin
https://www.readbyqxmd.com/read/29907952/bim-deletion-polymorphism-confers-resistance-to-osimertinib-in-egfr-t790m-lung-cancer-a-case-report-and-literature-review
#4
REVIEW
Xuanzong Li, Shijiang Wang, Butuo Li, Zhen Wang, Shuheng Shang, Yang Shao, Xindong Sun, Linlin Wang
The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib (AZD9291) has shown significant clinical efficacy against the EGFR T790M mutation in non-small cell lung cancer (NSCLC) patients. However, resistance inevitably occurs, and the mechanisms leading to treatment failure need to be further investigated. The B-cell lymphoma 2 (BCL-2)-like 11 (BIM) deletion polymorphism, which occurs at a frequency of 21% in East Asians but is absent in African and European populations, has been associated with resistance to first-generation EGFR TKIs, such as gefitinib and erlotinib; and is a poor prognostic factor for NSCLC patients with EGFR mutations...
June 16, 2018: Targeted Oncology
https://www.readbyqxmd.com/read/29907599/aggressive-b-cell-lymphomas-in-patients-with-myelofibrosis-receiving-jak1-2-inhibitor-therapy
#5
Edit Porpaczy, Sabrina Tripolt, Andrea Hoelbl-Kovacic, Bettina Gisslinger, Zsuzsanna Bago-Horvath, Emilio Casanova-Hevia, Emmanuelle Clappier, Thomas Decker, Sabine Fajmann, Daniela A Fux, Georg Greiner, Sinan Gueltekin, Gerwin Heller, Harald Herkner, Gregor Hoermann, Jean-Jacques Kiladjian, Thomas Kolbe, Christoph Kornauth, Maria-Theresa Krauth, Robert Kralovics, Leonhard Muellauer, Mathias Mueller, Michaela Prchal-Murphy, Eva Maria Putz, Emmanuel Raffoux, Ana-Iris Schiefer, Klaus Schmetterer, Christine Schneckenleithner, Ingrid Simonitsch-Klupp, Cathrin Skrabs, Wolfgang R Sperr, Philipp Bernhard Staber, Birgit Strobl, Peter Valent, Ulrich Jaeger, Heinz Gisslinger, Veronika Sexl
Inhibition of Janus-kinase 1/2 (JAK1/2) is a mainstay to treat myeloproliferative neoplasms (MPN). Sporadic observations reported the co-incidence of B-cell non-Hodgkin lymphomas during treatment of MPN with JAK1/2 inhibitors. We assessed 626 MPN patients including 69 with myelofibrosis receiving JAK1/2 inhibitors for lymphoma development. B-cell lymphomas evolved in 4/69 patients (5.8%) upon JAK1/2 inhibition compared to 2/557 (0.36%) with conventional treatment (16-fold increased risk). A similar 15-fold increase was observed in an independent cohort of 929 MPN patients...
June 14, 2018: Blood
https://www.readbyqxmd.com/read/29907552/beyond-maximum-grade-modernising-the-assessment-and-reporting-of-adverse-events-in-haematological-malignancies
#6
REVIEW
Gita Thanarajasingam, Lori M Minasian, Frederic Baron, Franco Cavalli, R Angelo De Claro, Amylou C Dueck, Tarec C El-Galaly, Neil Everest, Jan Geissler, Christian Gisselbrecht, John Gribben, Mary Horowitz, S Percy Ivy, Caron A Jacobson, Armand Keating, Paul G Kluetz, Aviva Krauss, Yok Lam Kwong, Richard F Little, Francois-Xavier Mahon, Matthew J Matasar, María-Victoria Mateos, Kristen McCullough, Robert S Miller, Mohamad Mohty, Philippe Moreau, Lindsay M Morton, Sumimasa Nagai, Simon Rule, Jeff Sloan, Pieter Sonneveld, Carrie A Thompson, Kyriaki Tzogani, Flora E van Leeuwen, Galina Velikova, Diego Villa, John R Wingard, Sophie Wintrich, John F Seymour, Thomas M Habermann
Tremendous progress in treatment and outcomes has been achieved across the whole range of haematological malignancies in the past two decades. Although cure rates for aggressive malignancies have increased, nowhere has progress been more impactful than in the management of typically incurable forms of haematological cancer. Population-based data have shown that 5-year survival for patients with chronic myelogenous and chronic lymphocytic leukaemia, indolent B-cell lymphomas, and multiple myeloma has improved markedly...
June 12, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29907126/nf-%C3%AE%C2%BAb-signaling-and-its-relevance-to-the-treatment-of-mantle-cell-lymphoma
#7
REVIEW
Swathi Balaji, Makhdum Ahmed, Elizabeth Lorence, Fangfang Yan, Krystle Nomie, Michael Wang
Mantle cell lymphoma is an aggressive subtype of non-Hodgkin B cell lymphoma that is characterized by a poor prognosis determined by Ki67 and Mantle Cell International Prognostic Index scores, but it is becoming increasingly treatable. The majority of patients, especially if young, achieve a progression-free survival of at least 5 years. Mantle cell lymphoma can initially be treated with an anti-CD20 antibody in combination with a chemotherapy backbone, such as VR-CAP (the anti-CD20 monoclonal antibody rituximab administered with cyclophosphamide, doxorubicin, and prednisone) or R-CHOP (the anti-CD20 monoclonal antibody rituximab administered with cyclophosphamide, doxorubicin, vincristine, and prednisone)...
June 15, 2018: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29906621/deoxynivalenol-decreased-the-growth-performance-and-impaired-intestinal-physical-barrier-in-juvenile-grass-carp-ctenopharyngodon-idella
#8
Chen Huang, Pei Wu, Wei-Dan Jiang, Yang Liu, Yun-Yun Zeng, Jun Jiang, Sheng-Yao Kuang, Ling Tang, Yong-An Zhang, Xiao-Qiu Zhou, Lin Feng
Deoxynivalenol (DON) is one of the most common mycotoxin contaminants of animal feed worldwide and brings significant threats to the animal production. However, studies concerning the effect of DON on fish intestine are scarce. This study explored the effects of DON on intestinal physical barrier in juvenile grass carp (Ctenopharyngodon idella). A total of 1440 juvenile grass carp (12.17 ± 0.01 g) were fed six diets containing graded levels of DON (27, 318, 636, 922, 1243 and 1515 μg/kg diet) for 60 days...
June 12, 2018: Fish & Shellfish Immunology
https://www.readbyqxmd.com/read/29905415/an-unusual-presentation-of-pulmonary-lymphoma-when-diffuse-ground-glass-opacities-can-mean-anything
#9
Anna Stainer, Paola Faverio, Francesca Bono, Alberto Pesci
Primary lung lymphoma (PLL) is a rare type of lymphoma confined to the lung at the time of diagnosis. Pulmonary diffuse large B cells lymphoma (P-DLBCL) is the second most common type of PLL and it usually appears radiologically as solitary or multiple nodules or areas of consolidation. We present the case of a 63-year-old Caucasian male who developed severe acute respiratory failure and diffuse ground glass opacities (GGO) on chest computerized tomography. Diffuse GGO may be the radiological expression of very different diseases, ranging from infectious processes to interstitial lung diseases (ILDs) and neoplastic diseases...
May 14, 2018: Monaldi Archives for Chest Disease, Archivio Monaldi Per le Malattie del Torace
https://www.readbyqxmd.com/read/29904934/common-gamma-chain-cytokines-promote-regulatory-t-cell-development-and-survival-at-the-cd4-cd8-stage-in-the-human-thymus
#10
Reetta Vanhanen, Anni Tuulasvaara, Joonatan Mattila, Tommi Pätilä, T Petteri Arstila
Thymic commitment of human FOXP3+ regulatory T cells begins at the double positive (DP) CD4+ CD8+ stage. In the current study we show that interleukin-2 promotes the development of FOXP3+ thymocytes and enhances their survival at the DP phase. IL-2 increases the frequency of FOXP3+ cells and promotes the Treg phenotype after TCR-mediated positive selection at the most mature DP stage. However, it has no effect on FOXP3+ cells at the earlier maturation steps before positive selection. DP FOXP3+ are highly susceptible to cell death but IL-2 promotes their survival...
June 15, 2018: Scandinavian Journal of Immunology
https://www.readbyqxmd.com/read/29904021/overcoming-resistance-of-human-non-hodgkin-s-lymphoma-to-cd19-car-ctl-therapy-by-celecoxib-and-histone-deacetylase-inhibitors
#11
Antoni Xavier Torres-Collado, Ali R Jazirehi
Patients with B-cell non-Hodgkin’s lymphoma (B-NHL) who fail to respond to first-line treatment regimens or develop resistance, exhibit poor prognosis. This signifies the need to develop alternative treatment strategies. CD19-chimeric antigen receptor (CAR) T cell-redirected immunotherapy is an attractive and novel option, which has shown encouraging outcomes in phase I clinical trials of relapsed/refractory NHL. However, the underlying mechanisms of, and approaches to overcome, acquired anti-CD19CAR CD8⁺ T cells (CTL)-resistance in NHL remain elusive...
June 14, 2018: Cancers
https://www.readbyqxmd.com/read/29903764/inferior-survival-in-high-grade-b-cell-lymphoma-with-myc-and-bcl2-and-or-bcl6-rearrangements-is-not-associated-with-myc-ig-gene-rearrangements
#12
Ellen D McPhail, Matthew J Maurer, William R Macon, Andrew L Feldman, Paul J Kurtin, Rhett P Ketterling, Rakhee Vaidya, James R Cerhan, Stephen M Ansell, Luis F Porrata, Grzegorz S Nowakowski, Thomas E Witzig, Thomas M Habermann
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (double-/triple-hit lymphoma) has an aggressive clinical course. We investigated prognostic value of transformation from low-grade lymphoma, cytologic features (high grade versus large cell), MYC gene rearrangement partners (immunoglobulin versus nonimmunoglobulin gene), and treatment. We evaluated 100 adults with double-/triple-hit lymphoma, reviewing cytologic features; cell of origin; and rearrangements of MYC, BCL2, and BCL6 using MYC, BCL2, and BCL6 break-apart and IGH/MYC, IGL/MYC, IGK/MYC, and IGH/BCL2 dual-fusion interphase fluorescence in situ hybridization probes...
June 14, 2018: Haematologica
https://www.readbyqxmd.com/read/29903707/valproate-in-combination-with-rituximab-and-chop-as-first-line-therapy-in-diffuse-large-b-cell-lymphoma-valfrid
#13
Kristina Drott, Hans Hagberg, Karin Papworth, Thomas Relander, Mats Jerkeman
The aims of the present study were to establish the maximally tolerated dose (MTD) of the histone deacetylase inhibitor valproate together with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with diffuse large B-cell lymphoma (DLBCL). A phase 1 dose escalation study of valproate together with R-CHOP followed by a dose expansion study using the established MTD of valproate was performed. MTD of valproate together with R-CHOP was established at 60 mg/kg per day, as higher doses resulted in auditory adverse events (AEs)...
June 26, 2018: Blood Advances
https://www.readbyqxmd.com/read/29902581/low-responsiveness-to-a-hepatitis-b-virus-vaccine-in-a-chinese-population-lacks-association-with-itgal-cd58-tnfsf15-ccl15-tgfb3-and-bcl6-gene-variants
#14
Xiaojia Xu, Yulian Li, Yaping Liang, Mingjuan Yin, Yan Zhang, Lingfeng Huang, Zuwei Yu, Jindong Ni
It is known that multiple genetic variants can affect immune responses to the hepatitis B virus (HBV) vaccine. A case-control study was undertaken to examine the possible association of low responsiveness to the HBV vaccine in a Chinese population with genetic polymorphisms in integrin subunit alpha L, CD58, tumor necrosis factor superfamily member 15, C-C motif chemokine ligand 15, transforming growth factor beta 3, and B-cell lymphoma 6 protein. The copy numbers of these six genes were detected in 129 low responders, 129 middle responders and 129 high responders to HBV vaccination...
June 11, 2018: Infection, Genetics and Evolution
https://www.readbyqxmd.com/read/29902576/lymphomas-with-pseudo-double-hit-bcl6-myc-translocations-due-to-t-3-8-q27-q24-are-associated-with-a-germinal-center-immunophenotype-extranodal-involvement-and-frequent-bcl2-translocations
#15
Steven M Johnson, Jayadev Manikkam Umakanthan, Ji Yuan, Yuri Fedoriw, R Gregory Bociek, Kathleen Kaiser-Rogers, Jennifer N Sanmann, Nathan D Montgomery
High-grade B-cell lymphomas with MYC, BCL2, and/or BCL6 rearrangements, "double hit" or "triple hit" lymphomas (DTHL), are aggressive neoplasms associated with a poor prognosis. A t(3;8)(q27;q24) rarely occurs in B-cell lymphomas that results in a unique "pseudo-double hit" BCL6-MYC fusion, indistinguishable by interphase fluorescence in situ hybridization (FISH) from more conventional DTHL with independent MYC and BCL6 translocations. Reports of t(3;8)(q27;q24) lymphomas are sparse, and to better characterize their pathologic, cytogenetic, and clinical features, 6 new cases from 2 institutions and 19 previously published cases were reviewed...
June 11, 2018: Human Pathology
https://www.readbyqxmd.com/read/29901189/protective-effects-of-scoparone-against-ischemia%C3%A2-reperfusion%C3%A2-induced-myocardial-injury
#16
Chunfu Wan, Yueyue Wei, Jianguo Ma, Xiaoyong Geng
The present study aimed to investigate the protective effects and molecular mechanisms of scoparone on ischemia‑reperfusion (I/R) injury in primary cultured cardiac myocytes and rats. An in vivo rat model of I/R injury and an in vitro primary cultured cardiac myocyte model of oxygen‑glucose deprivation/reoxygenation were used to investigate the protective effects of scoparone. Cell viability, lactate dehydrogenase (LDH) release, superoxide dismutase (SOD), creatine kinase (CK) and malondialdehyde (MDA) levels, and reactive oxygen species (ROS) production were subsequently measured...
June 4, 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29901138/upregulation-of-mir%C3%A2-122-is-associated-with-cardiomyocyte-apoptosis-in-atrial-fibrillation
#17
Xiangqun Zhang, Wenli Jing
Atrial fibrillation (AF) is a common cardiac arrhythmia, which is associated with increased cardiovascular morbidity and mortality. microRNA (miRNA/miR)‑122 has been reported to be related with heart diseases, however, the functional role of miR‑122 in atrial fibrillation is unclear. Therefore, the aim of the present study was to investigate the roles of miR‑122 in atrial fibrillation. Male C57BL/6 mice were divided into the following three groups: Control, sham‑operation and AF. Mice in the AF group received transesophageal rapid atrial stimulation for the induction of AF...
June 4, 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29901131/sequence%C3%A2-dependent-effect-of-sorafenib-in-combination-with-natural-phenolic-compounds-on-hepatic-cancer-cells-and-the-possible-mechanism-of-action
#18
Abdulmajeed A Bahman, Mohamed Salah I Abaza, Sarah I Khoushiash, Rajaa J Al-Attiyah
Sorafenib (Nexavar, BAY43‑9006 or Sora) is the first molecular targeted agent that has exhibited significant therapeutic benefits in advanced hepatocellular carcinoma (HCC). However, not all HCC patients respond well to Sora and novel therapeutic strategies to optimize the efficacy of Sora are urgently required. Plant‑based drugs have received increasing attention owing to their excellent chemotherapeutic and chemopreventive activities; they are also well tolerated, non‑toxic, easily available and inexpensive...
June 8, 2018: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/29901125/integrated-computational-biology-analysis-to-evaluate-target-genes-for-chronic-myelogenous-leukemia
#19
Yu Zheng, Yu-Ping Wang, Hongbao Cao, Qiusheng Chen, Xi Zhang
Although hundreds of genes have been linked to chronic myelogenous leukemia (CML), many of the results lack reproducibility. In the present study, data across multiple modalities were integrated to evaluate 579 CML candidate genes, including literature‑based CML‑gene relation data, Gene Expression Omnibus RNA expression data and pathway‑based gene‑gene interaction data. The expression data included samples from 76 patients with CML and 73 healthy controls. For each target gene, four metrics were proposed and tested with case/control classification...
June 5, 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29901111/dihydrocelastrol-exerts-potent-antitumor-activity-in-mantle-cell-lymphoma-cells-via-dual-inhibition-of-mtorc1-and-mtorc2
#20
Yongsheng Xie, Bo Li, Wenxuan Bu, Lu Gao, Yong Zhang, Xiucai Lan, Jun Hou, Zhijian Xu, Shuaikang Chang, Dandan Yu, Bingqian Xie, Yingcong Wang, Houcai Wang, Yiwen Zhang, Xiaosong Wu, Weiliang Zhu, Jumei Shi
Mantle cell lymphoma (MCL) is a distinct and highly aggressive subtype of B-cell non-Hodgkin lymphoma. Dihydrocelastrol (DHCE) is a dihydro-analog of celastrol, which is isolated from the traditional Chinese medicinal plant Tripterygium wilfordii. The present study aimed to investigate the effects of DHCE treatment on MCL cells, and to determine the mechanism underlying its potent antitumor activity in vitro and in vivo using the Cell Counting kit-8 assay, clonogenic assay, apoptosis assay, cell cycle analysis, immunofluorescence staining, western blotting and tumor xenograft models...
June 12, 2018: International Journal of Oncology
keyword
keyword
68620
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"